3/25/2024

Ciprofloxacin Injection

Products Affected - Description

- Ciprofloxacin injection, Pfizer, 2 mg/mL, 200 mL premixed bag, 24 count, NDC 00409-3300-24
- Ciprofloxacin injection, Sagent, 2 mg/mL, 100 mL premixed bag, 24 count, NDC 25021-0114-82
- Ciprofloxacin injection, Sagent, 2 mg/mL, 200 mL PVC/DEHP-free premixed bag, 24 count, NDC 25021-0192-87
- Ciprofloxacin injection, Sagent, 2 mg/mL, 200 mL premixed bag, 24 count, NDC 25021-0114-87

Reason for the Shortage

- Baxter discontinued ciprofloxacin injection in January 2023.
- Pfizer has ciprofloxacin injection on shortage due to manufacturing delays.
- Sagent did not provide a reason for the shortage.

Available Products

- Ciprofloxacin injection, Pfizer, 2 mg/mL, 100 mL premixed bag, 24 count, NDC 00409-2300-24

Estimated Resupply Dates

- Pfizer has ciprofloxacin 400 mg/200 mL premixed bags available in limited supply.
- Sagent has ciprofloxacin 200 mg/100 mL premixed bags on back order and the company cannot estimate a release date. The 400 mg/200 mL premixed bags are on allocation. The 400 mg/200 mL DEHP/PVC-free bags are on a limited allocation.

Updated

Updated March 25, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 13, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.